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A B S T R A C T
Recent years have seen a marked diversiﬁcation of excipient based formulation strategies used for the
development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches
not only provide beneﬁts to patients and health care professionals through the availability of a wider
range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential
opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and
continue to be developed using a single formulation excipient, the commercialisation of DPI products
which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual
excipient platform’ has recently been achieved. This article provides an overview of the background and
current status of the development of such ‘dual excipient platform’ based DPI products.
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Medicaments have been delivered to the respiratory tract for
thousands of years with this route of administration now
established as a standard and valuable drug delivery tool in the
physician’s armoury. Throughout history, the fundamental goal of
drug delivery to the lungs has essentially remained unchanged,
namely to generate and deliver a targeted efﬁcacious dose of active
ingredient to the patient. This is equally true in the modern
respiratory era where many approved drugs are now routinely
delivered to the patient using the very different, but well
understood delivery devices including pressurised metered dose
inhalers (pMDIs), nebulisers and DPI delivery platforms. As with
early forms of drug delivery to the respiratory tract, such modern
delivery systems also contain formulation ingredients other than
the drug substance. Whilst ancient texts, such as the Ebers
papayrus, and apothecaries may not have deﬁned them, most
ancient formulas, and indeed formulas until the end of the 19th
century, contained additional materials; what we would in the
present day refer to as, ‘excipients’ (Anderson, 2005; Sanders,
2007). Excipients now form one of the key cornerstones for the* Corresponding author.
E-mail address: r.price@bath.ac.uk (R. Price).
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development strategies are often progressed based on under-
standing the functionality of excipients, and, importantly, their
relationships to the processability and properties of any ﬁnal
dosage form. Since the primary task of development is to achieve
the commercialisation of pharmaceutical drug products which can
be manufactured consistently to meet deﬁned quality attribute
speciﬁcations, improvements that can be gained from any aspects
of the drug product manufacturing processes would be beneﬁcial
for patient outcomes. This is true for excipients, which often form
the major component of drug products, where their unique, and
importantly, multi-functional properties have allowed their use as
drug delivery vehicles in a wide range of dosage forms, including
respiratory products, including DPIs.
2. Respiratory therapy: the modern era and the dawn of the
excipient age
The modern era of drug delivery to the lungs using DPIs
essentially began in the 1940's with the appearance of the ﬁrst
approved commercial DPI product, namely the Abbott Aerohaler1,
from Abbott Laboratories, USA. This product was used to deliver
penicillin and norethisderone and contains many features which
would be recognisable today, in that it uses a small capsule
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formulation, designed to be used in a device which utilises the
patient generated inspiratory airﬂow to disperse the therapeutic
particles in an airstream (Fields, 1949; Sanders, 2007). It is
particularly interesting to note that in the original 1949 Abbott
Laboratories patent for this product, the inventor, Mack Fields,
described the rather insightful claim that ‘smoother and more
accurate mechanical action can be secured by mixing the penicillin
with at least a little other material intended to function as a diluent
or vehicle’, an early reference to the functionality, and importance,
of an additional ‘material’; i.e. the ‘excipient’.
Whilst many attributes, and concepts, of the Abbott Aerohaler1
are common in the current DPI arena, it was only in the 1960's with
the development of the single unit dose gelatin capsule based
product, the Intal1Spinhaler1, that researchers began to investi-
gate the potential applications and functionality of excipients in
DPIs. For example, as early as 1971 the importance of particle size
distribution characteristics for the dispersion of lactose and
formulations of (di)sodium cromoglycate and lactose from a
Spinhaler1 was described by Bell et al. (1971). The
Intal1Spinhaler1 proved to be the forerunner to the development
and commercialisation of many ‘drug only’ and excipient based DPI
products (Healy et al., 2014; Yang et al., 2014). Whilst the
formulation approaches to DPIs during this era of expansion
remained relatively unchanged, essentially using a ‘single excipi-
ent platform’ (SEP) based on a micronised drug substance and a
single excipient, lactose monohydrate, this period also saw further
advances in the scientiﬁc understanding of the interactions
between the components of DPI products, namely the drug
substance, excipient, container system and device. These scientiﬁc
advances have enabled the successful development of a techno-
logically diverse and elaborate range of excipient based reservoir,
capsule and blister formulation container closure systems for the
delivery of mono and combination drug therapies.
3. Excipient platforms in commercialised DPIs
Even though the development of DPI products requires a
somewhat different, and unique, set of considerations compared to
more standard oral solid dosage forms, it is important to remember
that the general role of excipients in DPI products is essentially the
same as for all pharmaceutical products, namely to impart
functionality to the formulation so as to enable the manufacture
of a robust, stable and reproducible drug product which maintains
its potency over its entire shelf-life. The establishment of a dose
range and dosing regimen provides an efﬁcacious and safe
medicine for the patient and development studies based on
identifying critical quality attributes using quality by design can
elucidate the approaches available to develop a commercial
product, thereby allowing appropriate product speciﬁcations to
be developed, and achieved. The tailoring of any such development
strategies can impact the development timelines and the product
performance and stability proﬁles and hence any achievable
product efﬁcacy and shelf-life. The solution of these often
conﬂicting challenges is the conundrum of pharmaceutical
development, for which excipients can play a key role. This is
especially true for DPI products, not only in view of their route of
administration, but also in that they are typically very low dose
products compared to standard oral solid dosage forms. Conse-
quently, robust and often specialised analytical methodologies and
techniques are required to control the qualities of the ﬁnal drug
product and its components during development and, importantly,
commercialisation.
The successful commercialisation of many mono and combina-
tion DPI drug therapies demonstrates that such development
challenges can be readily surmountable for micronised drugsubstances in SEPs. However, the turn of the 21st century has seen
a sea change in how users, and regulators, consider the wider
potential, applicability and control of excipients in DPI products.
For example, the importance of excipient quality, characteristics
and functionality is reﬂected not only in the increasingly
demanding regulatory and GMP frameworks for excipients, but
also by their inclusion in sections of the European and US
regulatory guidance for inhaled products, which form part of the
global regulatory environment for the submission of DPI product
dossiers to health authorities for obtaining marketing author-
isations.
4. The single excipient platform
The SEP has been the most prevalent excipient strategy used in
modern commercial DPI products and is deﬁned as a ﬁnal
formulation, which consists of one or more active pharmaceutical
ingredients (APIs) and a single excipient, regardless of any
blending, mixing and particle manipulation steps. The majority
of approved SEP DPI products have been developed based on the
well-known ‘carrier’ approach, however, the use of a single
excipient in DPI formulations now also encompasses systems
based on elaborate particle engineering technologies.
5. ‘Carrier’ based DPI formulations and products
As previously stated, many commercialised DPI products have
been developed based on using a single excipient in the formulation.
The vast majority of these products contain lactose monohydrate as
the excipient in so called ‘carrier’ and ‘agglomerate’ based
formulations where the excipient is used to aid the dosing of the
drug and to modify the cohesive nature of micronised drug
substances which directly inﬂuences DPI characteristics such as
blend uniformity, content uniformity, manufacturability and ulti-
mately, aerosol dose delivery performance characteristics. Indeed,
there is perhaps no other solid dosage formwhere so manyaspects of
the ﬁnal drug product manufacturing and performance are
dependent on the multi-functional properties of a single excipient.
However, it should be emphasised that while these SEP excipients
are described as ‘carriers’ for DPI products, their actual functionality
extends far further. For example, drug product expiry dates of 18–24
months at 25  Centrigrade storage conditions are readily achievable,
suggesting that a stable product can be commercialised without any
additional, and unnecessary and costly, formulation/excipient
manipulation. In such cases, the excipient may be providing stability
to the formulation and drug product, however, when the target
acceptable expiry date is achieved, any ‘stabilising’ functionality is
often not in evidence, or ‘claimed’.
5.1. The functionality of the ‘carrier’ excipient in SEP DPI formulations
and products
The role, or functionality, of the single excipient in SEP based
DPI products has traditionally been described as a ‘dispersant’,
‘ﬁller’, ‘diluent’ or ‘carrier’. In particular, the latter term is
somewhat unique to DPIs and was used as early as the 1970's
by Hartley and Gunning (1976) to describe the role of lactose in DPI
formulations of sodium chromoglycate. Investigations into the
physical properties of pharmaceutical powder mixtures began in
earnest in the 1970's and 1980's where researchers including
Travers, Hersey, and Staniforth, and their co-workers, published a
series of articles relating to the interactions between particles in
powder beds in what were then described as so-called ‘ordered
mixtures’ or ‘adhesive mixtures’ (Travers and White, 1971; Hersey,
1975; Lai et al., 1981; Staniforth et al., 1982). The importance of this
growing area of scientiﬁc interest was recognised in the British
Fig. 1. Scanning electron microscope image of spray-dried mannitol in Bronchitol1,
mag. 4000. Image with permission of University of Sydney.
376 J. Shur et al. / International Journal of Pharmaceutics 514 (2016) 374–383Pharmaceutical Conference Science Award Lecture ‘Order out of
Chaos’, presented by John Staniforth in 1986 (Staniforth, 1987).
Even though many of these early reports used the phrase ‘carrier’
to describe the larger particle sized component in binary powder
mixtures, these studies were primarily focused on the evaluation of
the properties of the powders in relation to standard tablet and
capsule based solid dosage forms, for example, segregation and
homogeneity, and not their rolein inhaledproducts.Sincethese early
fundamental studies a plethora of scientiﬁc literature, reviews and
patents has appeared describing the interactions of particles in
powder mixtures, including various aspects of ‘carrier’ based DPIs
and researchers are continuing to elucidate the relationships
between the properties of ‘carrier’ excipients and drug substances,
and their impact on pharmaceutical performance. For example, for
such formulations, it is nowaccepted that particle sizedistributionof
the ‘carrier’ excipient is critical for product performance, and
requires appropriate controls.
Additionally, the increasingly universal use of terms such as
‘adhesive mixture’ and ‘carrier’ to describe formulations and
excipients in DPIs has led to their appearance in regulatory
relevant documents. For example, in 2012, the description
‘adhesive mixture’ was used in the public European Committee
for Medicinal Products for Human Use (CHMP) assessment
documentation (EMA/CHMP/303918/2012) to describe the
micronised aclidinium bromide and lactose monohydrate formu-
lation in the DPI product, Bretaris1Genuair1. Moreover, the
‘carrier’ description is now so commonplace in academic,
industrial and regulatory circles that in 2014 it was incorporated
into the updated respiratory section of the United States
Pharmacopoeia general chapter <1059> Excipient Performance
(United States Pharmacopoeia, 2016) and also appears in the
public CHMP assessment documentation of several recently
approved DPI products, for example, EMA/659981/2009 for
Onbrez1Breezhaler1, approved in 2009. Such ‘carrier’ excipients,
often of a small particle size, are also used in what are described as
‘agglomerate’ formulations, where the functionality of the excipi-
ent is similar to the ‘carrier’ based systems, for example in
Symbicort1Turbohaler1.
Developing such SEP based products is a challenging and often a
semi-empirically driven process. However, pathways for the
development of lactose monohydrate based ‘carrier’ and ‘agglomer-
ate’ formulations containing micronsied drug substances presently
consist primarily of standard robust unit process operations, such as
micronisation, blending, ﬁlling and packaging. Even though the use
ofsuchprocesses inDPIproducts issomewhatuniquetothissectorof
the pharmaceutical industry, their impactonthe ﬁnal drug product is
well understood. These processes have been successfully used to
commercialise many originator, and more recently, generic DPI
products. Even though the vast majority of marketed SEP ‘carrier’
based DPI products contain lactose monohydrate, single excipient
‘carrier’/‘agglomerate’ based DPI products have also historically been
commercialised utilising anhydrous glucose (Atrovent1Aerocaps1)
and anhydrous lactose (Asmanex1Twisthaler1) in single dose
capsule and reservoir devices, respectively. Even though such
‘anhydroglucose’ containing excipients exhibit similar physico-
chemical characteristics to lactose monohydrate, the development
of DPI products using these alternative excipients is not without risk,
and represents the ﬁrst signs of a willingness to investigate and
innovate new excipient delivery platforms, an interesting indication
of future development scenarios.
6. Particle engineered single excipient based DPI formulations
and products
The use of excipients in SEP DPI products beyond the traditional
functional role of ‘carrier’ has also been realised with the approvalof Bronchitol1, approved in Europe in 2012 (EMA/CHMP/121817/
2012), and Afrezza1, approved in the US in 2014. The approval of
these two products not only represents advances in innovation in
the respiratory sector, but also a step change in the technological
and regulatory approaches to the so-called SEP, which should not
be underestimated in terms of their achievement. From the
publically available regulatory product reviews, patient informa-
tion and literature, both of these products not only contain
elaborately engineered particles but also novel DPI excipients, with
the former, developed by Pharmaxis, containing spray-dried
engineered mannitol, see Fig. 1 which is the actual efﬁcacious
agent (atypical active) (Hurt and Bilton, 2012), and the latter,
fumaryl diketopiperazine, see Fig. 2. Afrezza1 was originally
developed by MannKind Corporation as Technosphere1 for
delivery of insulin to the systemic circulation via the lungs and
this delivery platform is based on the elaborate self-assembly
properties of the propriety excipient, fumaryl diketopiperazine, a
substituted diketopiperazine (Leone-Bay and Grant, 2006). Man-
nitol is also marketed in several countries as Aridol1/Osmohale1, a
capsule based DPI indirect diagnostic osmotic bronchial challenge
test that can be used to identify bronchial hyper-responsiveness.
Additionally, other sophisticated SEP particle engineering tech-
nologies are also being developed for the respiratory sector by
companies such as Liquidia (Garcia et al., 2012).
Even though both the ‘carrier’ and, more recently, particle
engineering, SEP strategies continue to be successful and widely
used in commercialised DPIs, this does not mean that other,
multiple excipient based platforms, have not been explored by the
respiratory sector and DPI products based on using two or more
excipients indeed, have been commercialised. For example, the use
of multiple excipients in DPI products has been realised with the
approval of ExuberaTM, and more recently, TOBI1Podhaler1, but
perhaps the most notable and more broadly applied new excipient
platform strategy for the development of DPIs used to date is the
‘dual excipient platform’ (DEP) where lactose monohydrate is used
in conjunction with a second, ternary, excipient, namely magne-
sium stearate.
7. The dual excipient platform
Whilst the ‘carrier’ based SEP approach has been demonstrated
to be more than capable of supporting the development and
commercialisation of many originator, and to a lesser extent,
generic DPI products, there may be instances where the use of such
historical ‘single excipient’ approaches may not be appropriate for
the development of some DPI products, especially in standard
Fig. 2. Chemical structure of fumaryl diketopiperazine (FDKP).
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an SEP may not be capable of achieving the required performance
efﬁciency, manufacturability and scale or commercial shelf-life
using well understood product and company speciﬁc ‘carrier’
excipient based processing steps. Additionally, the SEP may not be
readily adaptable for intellectual property reasons or for the
matching of generic DPIs to their originator products.
In terms of new approaches for the commercialisation of DPI
products, recent development strategies have focused on main-
taining a well understood and established inhaler device, container
systems and manufacturing processes, whilst modifying the
functionality of the formulation by the addition of a single ternary
material, and in particular, an excipient, and most notably,
magnesium stearate; creating a ‘dual excipient platform’. Such a
DEP can be considered as a highly functional excipient system in
which a second (ternary) excipient is added during one or more of
the manufacturing unit operation(s) at a certain ﬁnal level to
impart a required property to the ﬁnal formulation and drug
product rather than any simple blending, mixing or manipulation
of the same single excipient. However, it should be considered that
any added material may also inadvertently impart functionality to
another aspect of the drug product in addition to modifying the
targeted functional characteristic, which is important for any
intellectual property considerations.
7.1. The dual excipient platform in commercial DPI products
Whilst there has been a considerable number of academic
publications and patents concerning the use of additional (ternary)
excipients as functional additives for DPIs, their use in approved
products has expanded since 2010 with no less than 6 product
approvals by 3 sponsors in global regional markets between 2010
and 2015, all of which contain lactose monohydrate and
magnesium stearate, see Table 1.
The approval of these products also demonstrates the
applicability of the ternary excipient, magnesium stearate, in
different lactose monohydrate based DPI delivery platforms,
namely, capsule, blister and reservoir. One interesting additional
aspect of such approvals is that the sponsors of these products
appear to be also adopting internal ﬂexible development
approaches in that they have commercialised products which
contain both a single excipient, lactose monohydrate, and productsTable 1
Approved lactose monohydrate/magnesium stearate dual excipient platform inhalation
Brand name Company/
MAHa
Drug 
Foster1NEXThaler1 Chiesi Beclometasone dipropiona
fumarate
Relvar1Ellipta1/BreoTM ElliptaTM GSK Vilanterol trifenatate/ﬂutic
Anoro1Ellipta1/AnoroTMElliptaTM GSK Umeclidinium bromide/vil
Incruse1Ellpta1 GSK Umeclidinium bromide 
Seebri1Breezhaler1/
SeebriTMNeohaler1
Novartis Glycopyrronium bromide 
Ultibro1Breezhaler1/
UtibronTMNeohaler1
Novartis Glycopyrronium bromide/i
a MAH, marketing authorisation holder.which contain two excipients, namely, lactose monohydrate
together with the ternary, additional, excipient, magnesium
stearate. In view of the number of successful capsule, blister and
reservoir based DPI product approvals which contain magnesium
stearate it can be argued that such a development strategy is now
becoming an industry and regulatory ‘standard’. However, the
successful development of any new excipient platform in DPIs
represents real scientiﬁc and technological innovation by the
industry.
7.2. The functionality of magnesium stearate in DEP DPI formulations
and products
Magnesium stearate is produced from animal and vegetable
sources and is a well-known excipient, which is widely used as a
lubricant is sold dosage forms. However, as with many excipients,
magnesium stearate is not a single pure chemical entity, and in this
case, the commercial excipient exists as a composite/mixture of
magnesium salts of stearic acid and palmitic acid (Allen and Luner,
2009). The traditional role of magnesium stearate in solid dosage
forms has also been expanded to DPIs where its functionality in
DEP formulations has been described in the literature as a
‘lubricant’, ‘force control agent’, ‘water barrier’, ‘stabiliser’ and
‘chemical stabiliser’, which are discussed in the following Sections,
suggesting multi-functional properties of this excipient in this
solid dosage form.
7.3. Magnesium stearate as a lubricant in DEP DPI formulations and
products
The pre-curser to what we now recognise as the DEP really
began in the 19800s. One of the ﬁrst roles for a ternary additional
material in a DPI product was described by Chiesi and Pavesi (1987)
for the alleviation of potential issues with the mechanical dosing
mechanism in a reservoir type DPI device. The functional property
of the ternary materials described, including magnesium stearate
and sodium benzoate, was described as a ‘lubricant’, which is the
widely accepted pharmaceutical functionality of such excipients
(Chiesi and Pavesi, 1987). The ﬁrst modern era DEP DPI product,
Pulvinal1Beclometasone1 (Chiesi), see Fig. 3, a lactose mono-
hydrate based reservoir device product, available in three dose
strengths of beclometasone dipropionate, which, according to the
patient information leaﬂet also, importantly, contained magne-
sium stearate, was approved in the UK in 2001. This was followed in
2004 by the approval of the Novartis reservoir based multi-dose
DPI product, Foradil1Certihaler1, which also used a DEP of lactose
and magnesium stearate. The approval of these two products
represents innovative and novel formulation approaches for the
commercialisation of DPI products.
However, even though the earlier Pulvinal1Beclometasone1
product was successfully developed and received a marketing drug products post 2010.
Therapy Dose
container
First approved
te/formoterol Combination, co-
formulated
Reservoir 2012
asone furoate Combination, dual Dual blister 2013
anterol trifenatate Combination, dual Dual blister 2013
Mono Single blister 2014
Mono Capsule,
HPMC
2012
ndacaterol maleate Combination, co-
formulated
Capsule,
HPMC
2013
Fig. 3. Pulvinal1Beclometasone1, the ﬁrst commercial lactose monohydrate/magnesium stearate DEP platform product. Image with permission from Chiesi.
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functionality advantages that such ternary materials may offer in
terms of DPI product performance.
7.4. Magnesium stearate as a performance enhancer in DEP DPI
formulations and products
It did not take long, however, before investigators began to
study the effect of ternary materials on the properties of powders
and DPI product performance. In terms of the use of magnesium
stearate, reports by workers such as Staniforth and co-workers had
already described the inﬂuence of a ternary component, magne-
sium stearate, on the adhesion of salicylic acid to sucrose
(Staniforth et al., 1982). Such observations were further elaborated
for the potential advantages of ternary materials for DPI product
performance and patents and scientiﬁc literature began to appear
at the turn of the 21st century, claiming that the addition of ternary
materials, such as magnesium stearate, could improve the ﬁne
particle dose performance characteristics of DPI formulations
(Brambilla et al., 2003; Chiesi et al., 2001; Musa et al., 2003;
Staniforth, 1997; Zhou and Moreton, 2012). Since this time many
patents have appeared describing the use of excipient ‘combina-
tions’, with these patents typically describing formulations
containing dual excipient ‘mixtures’ of lactose monohydrate and
a ternary material, including magnesium stearate. The use of
lactose monohydrate and magnesium stearate as an excipient
template for DPI development was further expanded with
technology platforms such as Powderhale1 (Vectura) and Sky-
eProtect1 (SkyePharma) appearing.
7.5. Magnesium stearate as a force control agent in DEP DPI
formulations and products
Whilst the use of such ternary materials in DEP DPI products
may now be considered to be a somewhat standard approach, it
should not be underestimated what this technological achieve-
ment represented in terms of modern DPI development and,
importantly, regulatory approval. With the increased understand-
ing of the surface and particulate interactions in DPIs (Price et al.,
2002; Begat et al., 2004; de Boer et al., 2012), the use of such
ternary materials in modern DPI development has led to thefunctionality of such a performance enhancer to also now being
widely referred to as a ‘force control agent’ (Begat et al., 2005;
Begat et al., 2009). Where such additives were added to DPIs their
function was invariably to modify the characteristics of the powder
formulation by impacting the inter-particulate interactions, or
‘cohesive-adhesive balance’ resulting in improved powder prop-
erties and aerosolisation performance.
7.6. Magnesium stearate as a water barrier in DEP DPI formulations
and products
It has been reported that the presence of magnesium stearate in
DPI lactose monohydrate formulations results in not only the
generation of a higher, but more stable ﬁne particle mass, which
was explained in terms of the functional ability of magnesium
stearate to protect the formulation from moisture, representing yet
another possible functional ‘stabilising’ role for ternary materials
in DPI products (Guchardi et al., 2008; Keller and Müller-Walz,
2001).
7.7. Magnesium stearate as a stabiliser in DEP DPI products
The previous sections described the functionality of the ternary
material magnesium stearate in DEP formulations and products. It
is clear that the presence of magnesium stearate can, in some cases,
impart beneﬁcial properties to DPI DEP formulation products and it
can be argued that any such improvements can be described, to
some degree, as stabilising effects. However, the true beneﬁt of any
possible improvements to any DPI performance characteristic can
only be fully elucidated after the evaluation of their performance
during stability assessment over a commercially acceptable shelf-
life.
Any decisions for pharmaceutical product development strate-
gies are based on both commercial and development consider-
ations. This is equally true for DPI products where the fundamental
goal of pharmaceutical development remains the same: to develop
the required marketed form of a drug product, whether this be for
an originator or generic product, in an appropriate timeframe.
Whilst this naturally focusses on the needs of patients in terms of
disease state, therapy, outcomes, compliance etc., the achievement
of an acceptable product shelf-life is a pre-requisite for the
Fig. 4. Examples of stability indicator proﬁles which may be encountered during
pharmaceutical stability studies. Adapted from Bowman (2007).
Fig. 5. Example of the ingress of moisture into aluminium blisters during storage at
25 C/60% RH. Adapted from Ziegler et al. (2008).
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challenge during development and the subsequent deﬁning of the
product speciﬁcations (Capen et al., 2012). Whilst early develop-
ment stability studies can provide indications of DPI product
performance and allow the assignment of a shelf-life in the various
global climate temperature and humidity zones there may be
situations where the expected stability proﬁle for commercialisa-
tion may not be achievable using standard and well understood
materials and processes, especially in SEP products. Clearly, in such
instances simple modiﬁcations of the manufacturing processes or
levels, and ranges, of functionality provided by the device/
container system, packaging, storage conditions, drug substance
or the single excipient may not be sufﬁcient to achieve, or
maintain, an acceptable level of a particular critical drug product
quality attribute.
In general, two types of stability proﬁles are exhibited by
pharmaceutical drug products during storage time namely,
constant and non-constant. The constant stability proﬁles consist
of quality attributes stability indicators which have little or no
variability during time when stored at the long term storage
condition, with any apparent changes being a consequence of
product or method variability. The non-constant stability proﬁles
contain quality attributes which either increase or decay during
storage at the long term storage condition. It is the products which
exhibit non-constant stability proﬁles which pose the greatest
challenge for the commercialisation of a product since an
acceptable shelf-life may not be achievable due to, for example,
the early occurrence of out of speciﬁcation events. Whilst out of
speciﬁcation results may not impact toxicity (e.g. not associated
with increased levels of impurities), they can sometimes impact
the efﬁcacy of the drug product. In many cases, any well
understood decaying or increasing speciﬁcation stability indicat-
ing parameter can be controlled to exhibit an acceptable sustained
stability proﬁle, allowing an acceptable shelf-life to be achieved,
represented for decaying stability proﬁles in Fig. 4. For example,
the rate of any detrimental physico-chemical interactions in the
product may be reduced by refrigeration, API salt form and
hydration state, formulation and device design and processing and
packaging conﬁgurations. However, such control measures may
not always readily achieve the required outcomes for some
development programs or be commercially viable and alternative
strategies need to be considered. This is especially true for capsule
and blister based DPI products, where, for example, any moisture
ingress occurring during storage may inﬂuence the long term
performance of the product, see Fig. 5.
7.8. The use of magnesium stearate as a stabiliser in DEP blister based
DPI products
From a development, scientiﬁc and innovation perspective,
perhaps the most interesting of the DEP approved products are the
GSK blister based products Relvar1Ellipta1/BreoTMElliptaTM and
Anoro1Ellipta1/AnoroTMElliptaTM, not only for their use of the
‘dual excipient platform’ but that they also utilise new device
delivery systems, albeit still blister based, compared to the
previous generation of products. These two products are combi-
nation products, but in contrast to the precursor combination
product, Seretide1Accuhaler1/AdvairTMDiskusTM, where the 2
APIs, salmererol xinafoate and ﬂuticasone propionate, are ‘co-
formulated’ into a single blister in a single blister strip, the two APIs
in Relvar1Ellipta1/BreoTMElliptaTM, namely vilanterol trifenatate
and ﬂuticasone furoate, and Anoro1Ellipta1/AnoroTMElliptaTM,
namely vilanterol trifenatate and umeclidinium bromide, are each
separately formulated into single mono therapy blisters in two
individual blister strips, within their respective dual blister
devices. This packaging strategy may be useful to avoid drug–drug incompatibility or formulation quality changes during
storage.
The public US prescribing information for the two new GSK
combination products suggest that the four mono drug formula-
tions in each of the two blisters in the two products contain
approximately 12.3  12.4 mg of lactose monohydrate so that the
total single formulation masses are 12.5 mg, with the public
European product characteristics information stating that the
delivered dose from the two products is approximately 25 mg of
lactose monohydrate. This single blister formulation ﬁll mass of
12.5 mg is similar to the formulation mass in the single blisters in
the Seretide1Accuhaler1/AdvairTMDiskusTM co-formulated com-
bination product. Additionally, the public US prescribing informa-
tion also states that the vilanterol trifenatate and umeclidinium
bromide formulations also contain magnesium stearate, at the
levels of 125 mg and 75 mg, respectively, see Table 2 for the
formulation compositions of Anoro1Ellipta1/AnoroTMElliptaTM.
These differences suggest that the magnesium stearate levels may
require adjusting in different formulations to optimise and achieve
the desired functional beneﬁts. Typical scanning electron micros-
copy images of the umeclidinium bromide and vilanterol trifenate
formulations in Anoro1Ellipta1 are shown in Fig. 6. It can be seen
Table 2
DEP excipient composition and functionality of the formulation components in the GSK products Anoro1Ellipta1/AnoroTMElliptaTM.
Formulation composition and functionalities
Vilanterol trifenatatea Umeclidinium bromideb
Drug contentc 40 mg 74.2 mg
Magnesium stearate massc 125 mg 75 mg
Magnesium stearate functionalityd Stabilisere Stabiliser
Lactose monohydrate massc to 12.5 mg to 12.5 mg
Lactose monohydrate functionalityd Diluent/carrier Diluent/carrier
% Magnesium stearate in formulationf 1.0% 0.6%
a Drug in combination products Anoro1Ellipta1/AnoroTMElliptaTM and Relvar1Ellipta1/BreoTMElliptaTM.
b Drug in combination product Anoro1Ellipta1/AnoroTMElliptaTM and the monotherapy IncruseTMElliptaTM.
c US prescribing information for AnoroTMElliptaTM.
d CHMP assessment report for Anoro1Ellipta1, EMA/CHMP/163509/2014.
e The CHMP assessment report EMA/282960/2013 describes magnesium stearate as a chemical stabiliser and stabiliser in the vilanterol trifenatate component of
Relvar1Ellipta1.
f Calculated for US product.
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which are typical for lactose based DPI formulations, suggesting
that the use of magnesium stearate in these DEP products has not
modiﬁed the macroscopic particle characteristics of the formula-
tions.
In contrast, from the public US prescribing information, the
related approved GSK mono therapy product Arnuity1Ellipta1
(ﬂuticasone furoate), the second drug component in
Relvar1Ellipta1/BreoTMElliptaTM, only contains the excipient
lactose monohydrate in the formulation, suggesting that in this
case, the functional properties of the formulation are sufﬁcient
without the addition of the ternary excipient, magnesium stearate.
However, the mono therapy of umeclidinium bromide,
IncruseTMElliptaTM, contains magnesium stearate at similar levels
to the umeclidinium bromide formulation in the combination
product, Anoro1Ellipta1/AnoroTMElliptaTM. This again demon-
strates the continuing ﬂexible, and innovative, development
approaches used during product development.
In terms of the functional development of ternary excipients in
such DEPs it is equally interesting to note that the public CHMP
assessments of Anoro1Ellipta1 and Relvar1Ellipta1 describes the
functionality of the magnesium stearate in the vilanterol
trifenatate formulation as both a ‘stabiliser’ and ‘chemical
stabiliser’, and in the umeclidinium bromide formulation as a
‘stabiliser’, with the functionality of lactose being described as a
‘carrier/diluent’, see Table 2. This ‘stabilising’ functionality
description is a widening of the accepted role and functionality
of such ternary agents and ‘force control agents’, and should not be
over-emphasised in terms of the implications for DPI development,
for both originator and generic products.Fig. 6. Scanning electron microscopy images of the lactose monohydrate/magnesium ste
Vilanterol trifenatate, mag. 1000. Images with permission from Nanopharm Ltd.In terms of stabilising ternary excipients used in DPIs, the use of
sugar esters, such as cellubiose acetate, to inhibit or reduce the
chemical interactions between an API and a carrier, and thereby
reducing chemical degradation, was described by Monteith and co-
workers (Monteith et al., 2006a,b). The use of ternary derivatised
carbohydrates was also reported to eliminate, or reduce, the
detrimental effects of storage conditions on the ﬁne particle dose
of DPI formulations (Bulsara and Roche, 2005). Similar observa-
tions were reported by Monteith and Thomas (2006), who
described the use of magnesium stearate as a ternary agent to
inhibit or reduce chemical interaction between an API and a carrier
in a solid pharmaceutical formulation, wherein the API is
susceptible to chemical interactions with the carrier. It was
suggested that the role of magnesium stearate, and sugar esters
such as cellubiose acetate, as inhibitors of chemical interactions
may be related to the ﬁndings that, under accelerated stability
conditions, certain inhalable APIs undergo degradation in the
presence of lactose. It was proposed that this type of chemical
reaction may proceed via the Maillard reaction, as suggested by
Wirth et al. (1998) for the drug Prosac1, who reported that drug
substances, which have secondary or primary amine moeities, as
have many small molecule respiratory drug substances, can
undergo the Maillard reaction with lactose under pharmaceutically
relevant conditions. However, many long acting beta agonist
respiratory drug substances in approved products, contain such a
similar N-substituted aminohydroxyethylbenzene type secondary
amine structures to vilanterol, for example, formoterol, indacaterol
and salmeterol, see Fig. 7. Moreover, commercialisation of the
latter 3 compounds in DPI products has been achieved without the
incorporation of any ternary excipient suggesting that, as expected,arate DEP formulations in Anoro1Ellipta1. A. Umeclidinium bromide, mag. x1000. B.
Fig. 7. Chemical structures of some long acting beta agonist respiratory drug substances in approved products showing the N-substituted aminohydroxyethylbenzene
secondary amine structure. A. Formoterol, B. Indacaterol, C. Salmeterol, D. Vilanterol.
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systems and shelf-life in DPI products are complex.
7.9. The use of magnesium stearate in DEP capsule based DPI products
The role of such DEPs based on lactose monohydrate and
magnesium stearate has also been demonstrated to be equally
applicable to other DPI platforms beyond blister based products.
Indeed, the public European product information and US
prescribing information for the two recently approved capsule
based products, the mono therapy Seebri1Breezhaler1/
SeebriTMNeohaler1 (glycopyrronium bromide), and the combina-
tion therapy Ultibro1Breezhaler1/UtibronTMNeohaler1 (glycopyr-
ronium bromide and indacaterol maleate), both developed by
Novartis, show that both the products also contain the two
excipients magnesium stearate and lactose monohydrate, see Fig. 8
and Table 3.
It is interesting to note that the indacaterol maleate component
in the co-formulated combination product Ultibro1Breezhaler1/
UtibronTMNeohaler1 is also approved as the mono therapies,
Onbrez1Breezhaler1/ArcaptaTMNeohalerTM in Europe and US,
respectively, but this product only contains lactose monohydrate.
This is similar to the excipient strategy diversity situation with theFig. 8. Seebri1Breezhaler1 and Ultibro1Breezhaler1 commercial lactose monohydpreviously discussed GSK mono and combination products and
again suggests that the functional properties of the indacaterol
maleate formulations in the mono therapies are sufﬁcient without
any additional magnesium stearate, further demonstrating the
continuing ﬂexible development approaches used during DPI
product development.
The public US prescribing information and European product
information also suggest that the two Novartis DEP products
contain similar masses of lactose monohydrate to the Novartis SEP
product, Onbrez1Breezhaler1/ArcaptaTMNeohalerTM, approxi-
mately 25 mg. Additionally, the public US prescribing information
for SeebriTMNeohaler1 and UtibronTMNeohaler1 also states that
the glycopyrronium bromide and glycopyrronium bromide/inda-
caterol maleate formulations also contain magnesium stearate, at
concentrations of 0.16% and 0.12%, respectively, see Table 3. This
small apparent difference in magnesium stearate levels for similar
mass formulations suggests that the functional beneﬁts of
magnesium stearate can vary between formulations. However, it
should be noted that the levels of magnesium stearate in the
Novartis DEP products are almost an order of magnitude lower
than the magnesium stearate levels in the GSK DEP products,
suggesting that the functional beneﬁts of a ternary material are
drug substance, formulation and product speciﬁc. Indeed it wasrate/magnesium stearate DEP products. ã 2016 Novartis. All Rights Reserved.
Table 3
DEP excipient composition and functionality in the formulation components in the Novartis DEP products SeebriTMNeohaler1 and UtibronTMNeohaler1.
Formulation composition and functionalities
Glycopyrronium bromidea Indacaterol maleate/Glycopyrronium bromideb
Drug contentc 15.6 mg 35.7 mg/15.6 mg
Magnesium stearate massc 0.04 mg 0.03 mg
Magnesium stearate functionality – –
Lactose monohydrate massc Approximately 25 mg Approximately 24.9 mg
Lactose monohydrate functionalityd Carrier Carrier
% Magnesium stearate in formulatione 0.16% 0.12%
a Drug in the monotherapy Seebri1Breezhaler1/SeebriTMNeohaler1.
b Drugs in the co-formulated combination product Ultibro1Breezhaler1/UtibronTMNeohaler1.
c US prescribing information, for US dosage strength.
d CHMP assessment reports, for European dosage strengths. Seebri1Breezhaler1, EMA/CHMP/508029/2012 and Ultibro1Breezhaler1, EMA/CHMP/296722/2013.
e Calculated for US Product.
Fig. 9. Foster1NEXThaler1 commercial lactose monohydrate/magnesium stearate
DEP product. Image with permission from Chiesi.
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amount of magnesium stearate in a DEP formulation would vary
depending on, for example, the API, and the particle size.
In terms of the functional development of ternary excipients in
the Novartis DEP products, the public CHMP assessments of
Seebri1Breezhaler1 and Ultibro1Breezhaler1 also describe the
functionality of the lactose monohydrate in both formulations as a
‘carrier’, see Table 3. Whilst there is no information concerning the
functionality of the magnesium stearate, the public CHMP
assessment of Seebri1Breezhaler1 describes some interesting
insights into the functionality of the excipients in this DEP product
in that the micronised active substance is described as being
‘stabilised by an added excipient’; another reference to the
stabilising functionality of excipients in DPI products. Additionally,
in contrast to the 2 DEP GSK products, where the public CHMP
assessments simply describe ‘blending’ manufacturing processes,
the public CHMP assessment of Seebri1Breezhaler1 describes the
manufacturing process of the ﬁnished product which involves the
preparation of a ‘pharmaceutical intermediate which is then
blended with excipients and ﬁlled into hard capsules’. The limited
availability of information concerning the manufacturing of the
blister and capsule based DEP products does indicate that different
process strategies may be being used to achieve the desired
outcomes, again reﬂecting the ﬂexible and innovative approaches
made during development.
Equally of interest is that for the 3 Novartis commercialised
products, Onbrez1Breezhaler1/ArcaptaTMNeohalerTM, Seebri1-
Breezhaler1/SeebriTMNeohaler1 and Ultibro1Breezhaler1/
UtibronTMNeohaler1 the public CHMP assessments and US
prescribing information suggest two different capsule types have
been used with hypromellose being used in the DEP products
Seebri1Breezhaler1/SeebriTMNeohaler1, and Ultibro1Breezhaler1/
UtibronTMNeohaler1, and gelatin in the SEP product, Onbrez1-
Breezhaler1/ArcaptaTMNeohalerTM. Since the hypromellose and
gelatin capsules have different characteristics, such as water content,
the use of different capsule materials offers another formulation
optionwhenconsideringdevelopmentstrategiesforDPIs(Richardson,
2011).
7.10. The use of magnesium stearate in DEP reservoir based DPI
products
The universality of the DEP would not be complete without its
use in reservoir based DPI products, which has, indeed, been
achieved. As previously mentioned, the ﬁrst modern commercial
DEP DPI product, Pulvinal1Beclometasone1, was developed by
Chiesi as a multi-dose reservoir based product, followed by the
Novartis multi-dose reservoir product Foradil1Certihaler1. Chiesi
have followed the same ‘reservoir’ based strategy with the
approval in 2012 of the DEP beclometasone dipropionate/formoterol fumarate co-formulated combination reservoir DPI
product, Foster1NEXThaler1, see Fig. 9. This again suggests that
the development strategies of pharmaceutical companies tend to
be based on attempting to minimise development risks by
manipulating formulations and using well understood, albeit
internal and often propriety, processing operations. The public
summary of product characteristics of Fostair1NEXThaler1 (the
UK brand of Foster1NEXThaler1), from 2014, states that the
product contains the two excipients, lactose monohydrate and
magnesium stearate, which is similar to the two excipients used in
the previously discussed commercial blister and capsule based DEP
DPI products.
8. Conclusions
For many decades DPI products have been successfully
developed using a variety of formulation strategies including drug
only or powder mixture approaches containing a single excipient,
typically lactose monohydrate. Single excipient based formula-
tions continue to be used in approved commercial DPI products
today. However, since 2010 there has been a major diversiﬁcation
in the formulation strategies successfully used and implemented
in approved DPI products. The early fundamental studies and
pharmaceutical innovations of Hersey, Monteith, Thomas, Stani-
forth, Chiesi etc., and their co-workers, has ﬁnally resulted in the
successful development, understanding and implementation of
J. Shur et al. / International Journal of Pharmaceutics 514 (2016) 374–383 383novel DEP strategies in commercialised DPI products. These
innovations have not only allowed the expansion of DPI develop-
ment options for pharmaceutical companies but, importantly, also
the availability of an increasing range of medicines that are
beneﬁcial to patients.
All trademarks referenced within this article are owned by the
respective third parties.
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